VIDO – Five Ways Our Research Strengthened Animal Health in 2025

Why It Matters

The breakthroughs strengthen Canada’s bio‑security, safeguard multi‑billion‑dollar livestock sectors, and deliver tangible tools for wildlife conservation, reinforcing the One Health paradigm.

Key Takeaways

• H5N1 infects dairy cows, triggers mastitis, natural immunity observed
• New bison TB vaccine improves diagnostics, protects cattle industry
• Koala chlamydia vaccine cuts mortality by 65%, global conservation impact
• ASF subunit vaccine advances, differentiates infected from vaccinated pigs
• Egg‑based chick vaccine targets Salmonella, boosts food safety

Pulse Analysis

The emergence of high‑pathogenic avian influenza in dairy cattle underscores how zoonotic threats can cross species barriers, prompting a shift toward proactive surveillance and vaccine development. VIDO’s containment studies not only clarified transmission pathways but also revealed that cattle can develop protective immunity after initial exposure, a finding that could inform broader pandemic preparedness strategies under the One Health framework. By collaborating with agencies such as the Canadian Food Inspection Agency and international networks, the organization positions Canada as a hub for rapid response to novel animal diseases.

Livestock industries worldwide face mounting pressure from pathogens that jeopardize trade and profitability. VIDO’s work on bovine tuberculosis in bison and subunit vaccines for African swine fever directly addresses these economic vulnerabilities. The new TB vaccine candidate, paired with improved diagnostics, aims to preserve Canada’s TB‑free status, while the ASF vaccine’s DIVA (differentiate infected from vaccinated animals) capability could keep export markets open by meeting stringent bio‑security standards. These advances illustrate how academic‑government partnerships can translate scientific insight into market‑ready solutions that protect billions in revenue.

Beyond farmed animals, VIDO’s contributions to wildlife health demonstrate the broader ecological and public‑health benefits of vaccine research. The koala chlamydia vaccine, built on a Canadian‑origin adjuvant, reduces mortality by more than 60%, offering a scalable model for other endangered species. Simultaneously, genomic analyses of E. coli in poultry and egg‑based Salmonella vaccination strategies enhance food safety from farm to fork. Collectively, these initiatives highlight a future where integrated research safeguards animal welfare, human health, and economic stability.